Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Judith M. Versluis(The Netherlands Cancer Institute), Alexander M. Menzies(The University of Sydney), Karolina Sikorska(The Netherlands Cancer Institute), Elisa A. Rozeman(The Netherlands Cancer Institute), Robyn P.M. Saw(The University of Sydney), Winan J. van Houdt(The Netherlands Cancer Institute), Hanna Eriksson(Karolinska University Hospital), W. Martin C. Klop(The Netherlands Cancer Institute), Sydney Ch’ng(The University of Sydney), Johannes V. van Thienen(The Netherlands Cancer Institute), Henk Mallo(The Netherlands Cancer Institute), Maria Gonzalez(The University of Sydney), A. Torres Acosta(The Netherlands Cancer Institute), Lindsay G. Grijpink-Ongering(The Netherlands Cancer Institute), A. van der Wal(The Netherlands Cancer Institute), Annemarie Bruining(The Netherlands Cancer Institute), Bart A. van de Wiel(The Netherlands Cancer Institute), Richard A. Scolyer(The University of Sydney), John B.A.G. Haanen(The Netherlands Cancer Institute), Ton N. Schumacher(Leiden University Medical Center), Alexander C. J. van Akkooi(The University of Sydney), Georgina V. Long(The University of Sydney), Christian U. Blank(Leiden University Medical Center)
Cited by 120Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis